National Health (Pharmaceutical Benefits - Early Supply) Amendment Instrument 2014 (No. 6) - specification under subsection 84AAA(2) (No. PB 75 of 2014) (Cth)

Case

PB 75 of 2014

National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 6) – specification under subsection 84AAA(2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 23 September 2014

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment determination – Pharmaceutical Benefits – Early Supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 6) – specification under subsection 84AAA(2).

(2)      This Instrument may also be cited as PB 75 of 2014.

2          Commencement

This Instrument commences on 1 October 2014.

3          Amendment of PB 30 of 2009

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).

Schedule 1        Amendments

  1. Schedule 1, entry for Aclidinium

omit from the column headed “Form”:

containing aclidinium bromide 400 micrograms per dose, 60 doses

substitute:

322 micrograms (as bromide) per dose, 60 doses

  1. Schedule 1, entry for Alendronic Acid

omit:

Tablet 40 mg (as alendronate sodium) Oral 30 5
  1. Schedule 1, entry for Oestradiol and oestradiol with dydrogesterone

insert as first entry in the columns in the order indicated:

Pack containing 14 tablets oestradiol 1 mg and 14 tablets oestradiol 1 mg with dydrogesterone 10 mg Oral 1 5
  1. Schedule 1, after entry for Oestradiol and oestradiol with norethisterone in the form Pack containing 4 transdermal patches
    780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg
    norethisterone acetate

insert:

Oestradiol with dydrogesterone Tablet 1 mg-5 mg Oral 28 5
Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0